Treatment of spasticity in multiple sclerosis: New perspectives regarding the use of cannabinoids;Tratamiento de la espasticidad en la esclerosis múltiple: Nuevas perspectivas con el uso de cannabinoides

Revista de Neurologia

Volumn 55, Issue 7, 2012, Pages 421-430

  Oreja Guevara, Celia ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cannabidiol; Cannabinoids; Delta 9 tetrahydrocannabinol; Endocannabinoid system; Multiple sclerosis; Pain; Spasticity

Indexed keywords

CANNABIDIOL; CANNABINOID; NABIXIMOLS; PLACEBO;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIPLE SCLEROSIS; REVIEW; SPASTICITY;

EID: 84867255279     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5507.2012362     Document Type: Review

References (47)

1. Noseworthy JH, Lucchinetti C, Rodríguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-95.
3. Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 2007; 78: 707-9.
4. De Sa J. Epidemiología de la esclerosis múltiple en Portugal y España. Rev Neurol 2010; 51: 387-92.
5. Modrego-Pardo PJ, Latorre MA, López A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997; 244: 182-5.
6. Aladro Y, Alemany MJ, Pérez-Vieitez MC, Amela R, Conde M, Reyes MP, et al. Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005; 24: 70-5.
7. Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, et al. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler 2012; Apr 30. [Epub ahead of print].
8. Fernández O, Fernández V, Guerrero M, León A, López-Madrona J, Alonso A, et al. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler 2012; 18: 372-6.
9. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
10. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6: 1-73.
11. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B; CDBE2010 Study Group, European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155-62.
12. Kobelt G. Health economic issues in MS. Int MS J 2006; 13: 17-26, 16.
13. Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Solino O, Pérez-Miranda J, et al, Asociación Española de Esclerosis Múltiple. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006; 7 (Suppl 2): S65-74.
14. De Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011; 4: 139-68.
15. Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil 2010; 24: 293-304.
16. Smith CR, LaRocca NG, Giesser BS, Scheinberg LC. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-31.
17. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; 4: CD001332.
18. Spasticity online survey results. MS in focus. URL: http:// www.msif.org/en/resources/msif_resources/msif_publications/ ms_in_focus/issue_12_spasticity_in_ms/spasticity_onlin. html. [23.02.2012].
19. Oreja-Guevara C, González D, Vila C, De Sola S. Multiple sclerosis spasticity in Spain: the '6E' patients' survey. Mult Scler J 2011; 17: S16.
20. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 205-13.
21. Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, Miquel-Rodríguez F, De Miguel-León I, Martínez-Garre MC, et al. Guía del tratamiento integral de la espasticidad. Rev Neurol 2007; 45: 365-75.
22. Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosisrelated spasticity. Expert Rev Neurother 2012; 12 (Suppl): S3-8.
23. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291-5.
24. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008; 4: 245-59.
25. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006; 12: 646-51.
26. Fernández-Ruiz J. Fármacos cannabinoides para las enfermedades neurológicas: ¿qué hay detrás? Rev Neurol 2012; 54: 613-28.
27. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
28. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147 (Suppl 1): S163-71.
29. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129-40.
30. Bisogno T, Di Marzo V. Cannabin receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 2010; 9: 564-73.
31. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007; 150: 519-25.
32. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-46.
33. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006; 42: 495-503.
34. Sastre-Garriga J, Vila C, Clissold S, Montalbán X. THC and CBD oromucosal spray (Sativex ®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011; 11: 627-37.
35. Vermersch P. Sativex (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert Rev Neurother 2011; 11: 15-9.
36. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
37. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-45.
38. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabisbased medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-6.
39. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebocontrolled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-9.
40. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al; Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-31.
41. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neurorehabilitation 2009; 24: 333-40.
42. Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult Scler 2007; 13.
43. Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult Scler 2009; 15: S272.
44. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012; 18: 219-28.
45. Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009; 32: 41-7.
46. Schoedel KA, Chen N, Guy GW, Wright S, Patel A, White L, et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur Neuropsychopharmacol 2010; 20 (Suppl 3): S587.
47. Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-85.